AcelRx Pharmaceuticals, Inc ACRX Stock Price Today, Quote & News

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value.

Brigham and Women’s Hospital study found that SST-treated patients had significantly lower pain scores in the post-operative care unit compared with patients in the two intravenous opioid contr… Study is the first to report on the use of DSUVIA® in the rapidly growing field of rhinology where otolaryngologists are performing painful nasal and sinus procedures in the office which were historic… Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA Breakthrough designation in line with a s… In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant AcelRx announces full repayment of its senior loan with Oxford Finance HAYWARD, Calif. ,…

A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. The price-earnings ratio is a company’s share price to the company’s Earnings per Share. The ratio is used for evaluating companies and to find out whether they are overvalued or undervalued. The price-to-book ratio is a company’s current market price to its Book Value. Traditionally, any value under 1.0 is considered a good P/B value, indicating a potentially undervalued stock.

AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock

Net money flow is the value of uptick trades minus the value of downtick trades. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Technology, Industrials and Oil & Gas sectors propelled shares lower. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Overview

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. Intraday Data provided by FACTSET and subject to terms of use. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Enterprise Value is a measure of a company’s total value, often used as a more comprehensive alternative to equity market capitalization.

Access advanced stock screeners, portfolio monitoring tools, proprietary research reports, and more. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction. AcelRx Pharma reported Q1 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $442 thousand versus the consensus estimate of $550… Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Oil & Gas, Technology and Consumer Goods sectors propelled shares higher.

AcelRx Pharmaceuticals cut to hold from buy at Jefferies

Enterprise value includes in its calculation the collateral harm in a sentence words in a sentence capitalization of a company but also short-term and long-term debt as well as any cash on the company’s balance sheet. Market cap or market capitalization is the total market value of all of a company’s outstanding shares. Represents the company’s profit divided by the outstanding shares of its common stock. AcelRx Pharmaceuticals shares reverse split before market open on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock.

AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year.

It’s calculated by averaging the closing stock price over the previous 50 trading days. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals.

These returns cover a period from January 1, 1988 through April 3, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

AcelRx Pharma Reports In-Line Q1 EPS

BOSTON — Shares of AcelRx Pharmaceuticals rallied nearly 30% to $3.47 on Tuesday on news that it has made progress complying with certain U.S. regulatory requests related to the initiation of Phase III clin… By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. 10 people have searched for ACRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. AcelRx Pharmaceuticals has received a 53.29% net impact score from Upright.

• Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
• Real-time quotes, advanced visualizations, backtesting, and much more.
• Intraday data delayed at least 15 minutes or per exchange requirements.
• Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.

We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and accommodation requests. Long term indicators fully support a continuation of the trend. These three penny stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching. Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA… Your browser of choice has not been tested for use with Barchart.com.

NEW YORK — Shares of AcelRx Pharmaceuticals plummeted 39% in active, premarket trade Monday, after the drug company said the U.S. Food and Drug Administration surprisingly requested and additional study to … This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies. AcelRx Pharmaceuticals delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. AcelRx Pharmaceuticals delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022.

To see all https://1investing.in/ delays and terms of use please see Barchart’s disclaimer. AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm’s portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes.

Barchart Technical Opinion

Provide specific products and services to you, such as portfolio management or data aggregation. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CompareACRX’s historical performanceagainst its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.

View the ACRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the AcelRx Pharmaceuticals Inc real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACRX quote. AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006.

• MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
• An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
• Acelrx Pharmaceuticals Inc 52 week high is $7.60 as of May 01, 2023.
• ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
• Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more. There may be delays, omissions, or inaccuracies in the Information. To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.